As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Similar Posts
Public advised to stop using certain non-sterile alcohol-free wipes
Due to risk of infection, non-sterile alcohol-free wipes are not appropriate for the treatment of injuries, wounds or on broken skin, nor for cleaning of intravenous lines.
Decentralised manufacture: The designation step
MHRA’s mechanism for evaluating the justifications supplied by applicant organisations who plan to utilise decentralised manufacture.
Guidance: Timelines for acceptance of CE marked medical devices in Great Britain (GB)
Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated tablets, distributed by Healthcare Pharma Limited.
Guidance: The Innovative Devices Access Pathway (IDAP)
The Innovative Devices Access Pathway (IDAP) pilot is designed to accelerate the development of innovative medical devices that meet an unmet clinical need in the NHS and support their integration into the UK market.
Electronic Common Technical Document (eCTD) submissions update
Since, April 2024, the MHRA has been using Lorenz DocuBridge for eCTD management in product license submissions. This change is part of the modernisation of the MHRA’s Legacy Systems and is one of the initial tools launched in the RegulatoryConnect programme.